A Study on the Efficacy of Three-Dimensional CT Bronchial Angiography in Thoracoscopic Precision Resection of Lung Segments.

Objective: This study aimed to evaluate the effectiveness of three-dimensional CT bronchial angiography (3D-CTBA) in facilitating precise lung segmental resection. Methods: A total of 80 patients with peripheral lung nodules undergoing anatomical lung segmentectomy were randomly divided into two groups: a control group (n = 40) and a study group (n = 40). The control group received surgical treatment based on chest CT prompts and traditional lung segmentation, while the study group's chest CT imaging data were reconstructed into 3D images before surgery, followed by lung segmentectomy. Surgical parameters and complication rates were compared between the two groups. Results: The study group exhibited significantly shorter operation time, drainage time, and hospitalization time, as well as reduced intraoperative bleeding, lung tissue resection size, and drainage volume, compared to the control group (P < .05). Hospitalization costs did not differ significantly between the two groups (P > .05). The incidence of lung infection, pulmonary atelectasis, and arrhythmia showed no significant difference between the groups (P > .05). However, the study group demonstrated significantly lower rates of hemoptysis and lung leakage compared to the control group (P < .05). There was no significant difference in the composition of postoperative pathological staging between the two groups (χ2 = 0.721, P > .05). Conclusions: The application of 3D-CTBA technology provides clear visualization of the lung's anatomical structure and contributes to enhanced safety and effectiveness in thoracoscopic lung segmental precision resection.

Research progress on effects of traditional Chinese medicine on myocardial ischemia-reperfusion injury: A review.

Ischemic heart disease (IHD) is a high-risk disease in the middle-aged and elderly population. The ischemic heart may be further damaged after reperfusion therapy with percutaneous coronary intervention (PCI) and other methods, namely, myocardial ischemia-reperfusion injury (MIRI), which further affects revascularization and hinders patient rehabilitation. Therefore, the investigation of new therapies against MIRI has drawn great global attention. Within the long history of the prevention and treatment of MIRI, traditional Chinese medicine (TCM) has increasingly been recognized by the scientific community for its multi-component and multi-target effects. These multi-target effects provide a conspicuous advantage to the anti-MIRI of TCM to overcome the shortcomings of single-component drugs, thereby pointing toward a novel avenue for the treatment of MIRI. However, very few reviews have summarized the currently available anti-MIRI of TCM. Therefore, a systematic data mining of TCM for protecting against MIRI will certainly accelerate the processes of drug discovery and help to identify safe candidates with synergistic formulations. The present review aims to describe TCM-based research in MIRI treatment through electronic retrieval of articles, patents, and ethnopharmacology documents. This review reported the progress of research on the active ingredients, efficacy, and underlying mechanism of anti-MIRI in TCM and TCM formulas, provided scientific support to the clinical use of TCM in the treatment of MIRI, and revealed the corresponding clinical significance and development prospects of TCM in treating MIRI.

Chinese Herbal Medicines for Restenosis After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

Objectives: This study evaluates the efficacy of Chinese herbal medicines after percutaneous coronary intervention (PCI). Background: PCI is the primary treatment for coronary atherosclerotic heart disease (CHD). However, many patients experience restenosis within 6 months after PCI. Chinese herbal medicines are widely used in patients after PCI. Clinical studies have found that Chinese herbal medicines may prevent restenosis. Methods: Eight databases were searched for randomized controlled trials (RCTs) investigating the use of Chinese herbal medicines after PCI. The search period was from the date of database inception to June 2017. We used the Cochrane risk of bias tool to estimate the methodological quality of the studies. The primary outcome was the restenosis rate, and secondary outcomes were the angina recurrence rate and major adverse cardiac events (MACEs). Data were analyzed with RevMan 5.3, and the quality of evidence was assessed with the GRAD approach. Results: Eleven RCTs with a total of 1,383 patients were included. The major outcome was the restenosis rate, and the results showed a significant effect of Chinese herbal medicines on reduction in the rate of restenosis (risk ratio [RR] = 0.46, 95% CI: 0.35-0.60, p < 0.00001, I2 = 0%). Chinese herbal medicine treatment also decreased the angina recurrence rate (RR = 0.41, 95% CI: 0.29-0.57, p < 0.00001, I2 = 0%). The results revealed a lower rate of MACEs in the Chinese medicine group than in the control group (RR = 0.49, 95% CI: 0.34-0.71, p = 0.0001, I2 = 0%). We evaluated the quality of evidence with the GRADE system; the quality of evidence for the restenosis rate and angina was low, and the quality of evidence for MACEs was estimated to be moderate. Conclusion: According to existing research evidence, the use of Chinese herbal medicines may reduce the incidence of MACEs. Chinese herbal medicines may reduce restenosis and angina recurrence rates after PCI, but the evidence is limited.